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Purpose: To describe the use of nepafenac 0.1% for cystoid macular edema (CME).
Methods: This was a multicenter retrospective review of 22 CME cases (20 patients) treated 
with nepafenac 0.1% (six with concomitant prednisolone acetate 1%) from December 2005 to 
April 2008: three acute pseudophakic CME cases, 13 chronic/recalcitrant pseudophakic CME 
cases, and six cases of uveitic CME. Pre- and post-treatment retinal thickness and visual acuity 
were reported.
Results: Following treatment for six weeks to six months, six eyes with uveitic CME showed 
a mean retinal thickness improvement of 227 ± 168.1 μm; mean best-corrected visual acuity 
(BCVA) improvement was 0.36 ± 0.20 logMAR. All three cases of acute pseudophakic CME 
improved after four to 10 weeks of nepafenac, with a mean improvement in retinal thickness of 
134 ± 111.0 μm. BCVA improved in two patients (0.16 and 0.22 logMAR) but not in the third 
due to underlying retinal pigment epithelium changes. Thirteen eyes with chronic/recalcitrant 
pseudophakic CME demonstrated a mean improvement in retinal thickness of 178 ± 128.7 μm 
after nepafenac and mean BCVA improvement of 0.33 ± 0.19 logMAR.
Conclusion: The positive outcomes of these 22 eyes strongly suggest that nepafenac 0.1% 
is a promising drug for the treatment of CME. Additional study under randomized controlled 
conditions is warranted.
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Introduction
Cystoid macular edema (CME) is a serious consequence of cataract surgery and other 
ocular procedures and conditions, resulting sometimes in transient or even permanent 
vision loss. The incidence of subclinical, angiographic CME is approximately 
20%–30% of uncomplicated cataract surgery cases,1,2 while acute, clinically signiﬁ  cant 
CME has been reported from 1%–2% of patients following uncomplicated phacoemul-
siﬁ  cation.3,4 Macular edema secondary to uveitis is also a common problem, occurring 
in up to 48% of uveitic eyes.5
Many studies have shown an association between CME and inﬂ  ammation.6–9 For 
this reason, CME is commonly treated with anti-inﬂ  ammatory agents. Corticosteroids 
can effectively prevent and treat CME,10,11 but are associated with serious side effects, 
including elevated intraocular pressure (IOP), posterior subcapsular cataract, and 
exacerbation of and increased susceptibility to concomitant infections.12–14 Thus, safer 
alternative treatments are desirable.
Topical nonsteroidal anti-inﬂ  ammatory drugs (NSAIDs) have demonstrated efﬁ  cacy 
in prophylaxis and/or treatment of CME.15–19 Because corticosteroids and NSAIDs 
inhibit prostaglandin synthesis by different mechanisms, an additive or synergistic effect 
is possible with combined therapy. Studies have conﬁ  rmed the beneﬁ  ts of combination 
therapy10,20 and it is now widely accepted that a combination of NSAID + steroid be initiated 
upon documentation of clinical CME.21 Although none of the approved topical NSAIDs Clinical Ophthalmology 2009:3 148
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have an indication for the treatment or prevention of CME, this 
accounts for widespread off-label use of these drugs.
The newest topical NSAID to earn Food and Drug 
Administration (FDA) approval for the treatment of pain and 
inﬂ  ammation associated with cataract surgery is nepafenac 
0.1% (Nevanac®). Nepafenac is the only topical NSAID 
with a prodrug structure; nepafenac is converted to its more 
active metabolite amfenac by intraocular hydrolases present 
in vascular ocular tissues, including the retina/choroid.22 Case 
series have already been reported suggesting that nepafenac 
0.1% has activity against various etiologies of CME.23,24 The 
retrospective cases presented below add to the evidence that 
the off-label use of nepafenac 0.1% is effective as treatment 
for pseudophakic and uveitic CME.
Methods
A retrospective review was performed on 22 cases (20 patients) 
of documented CME from four academic centers treated 
between 2005 and 2008 with nepafenac 0.1% (Nevanac®, 
Alcon Laboratories, Inc., Fort Worth, TX, USA) three times 
daily (TID). These cases were chosen for their representative 
response to nepafenac treatment. CME was documented by 
observing retinal edema on optical coherence tomography 
(OCT) using a Stratus OCT 3 (Carl Zeiss Meditec, Inc., Dublin, 
CA) and a reduction in Snellen best-corrected visual acuity 
(BCVA). Acute pseudophakic CME was deﬁ  ned as untreated 
CME with a duration of less than six months, whereas chronic 
pseudophakic CME was classiﬁ  ed as any CME persisting for 
at least six months. CME that had failed prior therapy was 
labeled recalcitrant. Nepafenac treatment was discontinued 
when substantial improvements in visual acuity and/or retinal 
thickness were documented. The speciﬁ  c cases presented 
below are representative examples of each type of CME.
Results
Uveitic CME
Five of the six uveitic eyes were recalcitrant to previous CME 
therapy, with four failing ketorolac + prednisolone acetate 1% 
and one failing prednisolone alone (Table 1). After six weeks 
to six months of treatment with nepafenac 0.1% TID (three 
eyes received concurrent prednisolone acetate 1%), CME 
improved in all six eyes. Retinal thickness decreased by an 
average of 227 ± 168.1 μm and vision improved by an aver-
age of 0.36 ± 0.20 logMAR.
Patient #1
A 42-year-old man presented with bilateral recalcitrant 
CME secondary to pars planitis. He had failed previous 
combination therapy with prednisolone acetate 1% and 
ketorolac 0.4% (Acular LS®, Allergan, Inc., Irvine, CA, USA) 
for eight months. His BCVA at the time of presentation was 
20/80 in the right eye and 20/100 in the left eye. The left 
eye, which had a central retinal thickness of 667 μm, was 
treated with intravitreal triamcinolone. Four weeks later (after 
administration of triple IOP-lowering drops decreased IOP 
from 56 mmHg to 22 mmHg), the retinal thickness in the 
left eye had decreased to 204 μm and BCVA had improved 
to 20/25. Instead of injecting the right eye with intravitreal 
triamcinolone, as the patient was now a known “steroid 
responder”, the decision was made to treat three times 
daily (TID) with nepafenac 0.1% for three months. At the 
completion of therapy, right eye central retinal thickness had 
decreased from 695 μm to 164 μm and BCVA had improved 
to 20/20 (Figure 1).
Acute pseudophakic CME
For the three cases of acute pseudophakic CME, improvement 
occurred after 4–10 weeks of treatment with nepafenac 0.1% 
with or without prednisolone acetate 1% (Table 2). One of 
the three patients did not achieve an improvement in vision, 
but this was due to underlying retinal pigment epithelium 
(RPE) changes from dry age-related macular degeneration 
rather than any residual edema.
Patient #6
A 75-year-old woman was diagnosed with CME in the right 
eye one month after uncomplicated phacoemulsiﬁ  cation 
and posterior chamber intraocular lens (IOL) implantation, 
showing a central retinal thickness of 448 μm and visual 
acuity of 20/50. She was started on treatment with nepaf-
enac 0.1% TID and prednisolone acetate 1% QID (four 
times daily); within one month of treatment the CME had 
completely resolved, with a retinal thickness of 211 μm and 
BCVA of 20/40 (Figure 2). Upon completion of the remainder 
of her medication, her vision improved further to 20/30.
Chronic/recalcitrant pseudophakic CME
Pseudophakic CME cases that met the criteria for chronic and/
or recalcitrant CME were grouped together. Nine of the 13 eyes 
in this category had been treated unsuccessfully with combina-
tion old generation NSAID/prednisolone therapy for as long 
as 16 months (Table 3). Of the remaining four eyes, two were 
treated with prednisolone acetate 1% alone, one was treated 
with ketorolac 0.5% alone, and the other had received no 
prior treatment. After 1–8 months of treatment with nepafenac 
0.1% (two eyes were treated concomitantly with prednisolone Clinical Ophthalmology 2009:3 149
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acetate 1%), improvement in retinal thickness was observed in 
all cases but one. At the most recent visit, these eyes showed 
a mean decrease in retinal thickness of 178 ± 128.7 μm and a 
mean improvement in visual acuity of 0.33 ± 0.19 logMAR. 
Five of the 13 eyes continue to receive nepafenac 0.1% in an 
attempt to produce complete resolution of CME.
Patient #12
A 69-year-old woman was diagnosed with CME in the right 
eye after undergoing uncomplicated cataract surgery. She was 
initially treated with ketorolac 0.5% and prednisolone acetate 
1% for six months, but failed to respond to therapy; OCT image 
after treatment showed a retinal thickness of 690 μm and visual 
acuity was 20/60 (Figure 3). Ketorolac and prednisolone were 
discontinued and nepafenac was initiated. One month after TID 
administration of nepafenac 0.1% alone, retinal thickness had 
improved to 262 μm and BCVA was 20/30.
All highlighted patients were representative of the other 
patients within each category.
Discussion
Although no randomized, controlled clinical trials have 
yet been reported on the ability of nepafenac 0.1% to treat 
CME, evidence is mounting that this drug has promis-
ing activity against macular edema of varying etiologies. 
One recently reported case series illustrates the positive impact 
A. Prior to nepafenac treatment B. After 3 months of nepafenac treatment
OD OD
Signal Strength (Max 10) Signal Strength (Max 10)
Analysis Confidence Low
5 4
270
274
260
Microns
502
564
442
417 695 290
244
246
216
280
251
263
276 164 229
Microns
Figure 1 Recalcitrant uveitic CME: Patient #1 OCT images. A) The patient shows 
retinal edema and cystoid spaces (see arrow), with a retinal thickness of 695 μm prior 
to nepafenac treatment. B) The patient shows resolution of retinal edema, with a retinal 
thickness of 164 μm after three months of nepafenac treatment.
Abbreviations: CME, cystoid macular edema; OCT, optical coherence tomography.
T
a
b
l
e
 
2
 
D
e
t
a
i
l
s
 
o
f
 
t
h
r
e
e
 
c
a
s
e
s
 
o
f
 
a
c
u
t
e
 
p
s
e
u
d
o
p
h
a
k
i
c
 
c
y
s
t
o
i
d
 
m
a
c
u
l
a
r
 
e
d
e
m
a
 
t
r
e
a
t
e
d
 
w
i
t
h
 
n
e
p
a
f
e
n
a
c
 
0
.
1
%
C
a
s
e
P
r
e
-
t
r
e
a
t
m
e
n
t
 
r
e
t
i
n
a
l
 
t
h
i
c
k
n
e
s
s
 
(
μ
m
)
P
o
s
t
-
t
r
e
a
t
m
e
n
t
 
r
e
t
i
n
a
l
 
t
h
i
c
k
n
e
s
s
 
(
μ
m
)
R
e
t
i
n
a
l
 
t
h
i
c
k
n
e
s
s
 
i
m
p
r
o
v
e
m
e
n
t
 
(
μ
m
)
P
r
e
-
t
r
e
a
t
m
e
n
t
 
V
A
 
(
l
o
g
M
A
R
 
V
A
)
P
o
s
t
-
t
r
e
a
t
m
e
n
t
 
V
A
 
(
l
o
g
M
A
R
 
V
A
)
V
A
 
i
m
p
r
o
v
e
m
e
n
t
 
(
l
o
g
M
A
R
)
T
r
e
a
t
m
e
n
t
#
6
4
4
8
2
1
1
2
3
7
2
0
/
5
0
 
(
0
.
4
0
)
2
0
/
3
0
 
(
0
.
1
8
)
0
.
2
2
N
e
p
a
f
e
n
a
c
 
0
.
1
%
 
T
I
D
 
a
n
d
 
p
r
e
d
n
i
s
o
l
o
n
e
 
a
c
e
t
a
t
e
 
1
%
 
Q
I
D
 
8
 
w
e
e
k
s
#
7
3
8
0
2
3
6
1
4
4
2
0
/
8
0
 
(
0
.
6
0
)
2
0
/
8
0
 
(
0
.
6
0
)
0
N
e
p
a
f
e
n
a
c
 
0
.
1
%
 
T
I
D
 
4
 
w
e
e
k
s
#
8
3
0
6
2
8
4
2
2
2
0
/
4
0
 
(
0
.
3
0
)
2
0
/
3
0
 
+
 
2
 
(
0
.
1
4
)
0
.
1
6
N
e
p
a
f
e
n
a
c
 
0
.
1
%
 
T
I
D
 
1
0
 
w
e
e
k
s
T
o
t
a
l
 
m
e
a
n
 
d
a
t
a
 
±
 
S
D
3
7
8
 
±
 
7
1
.
0
2
4
4
 
±
 
4
0
.
4
1
3
4
 
±
 
1
1
1
.
0
0
.
4
3
 
±
 
0
.
1
5
0
.
3
1
 
±
 
0
.
2
5
0
.
1
3
 
±
 
0
.
1
1
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
Q
I
D
,
 
f
o
u
r
 
t
i
m
e
s
 
d
a
i
l
y
;
 
S
D
,
 
s
t
a
n
d
a
r
d
 
d
e
v
i
a
t
i
o
n
;
 
T
I
D
,
 
t
h
r
e
e
 
t
i
m
e
s
 
d
a
i
l
y
;
 
V
A
,
 
v
i
s
u
a
l
 
a
c
u
i
t
y
.Clinical Ophthalmology 2009:3 151
Treatment of CME with nepafenac 0.1%
The conversion of the prodrug nepafenac into its more 
active metabolite, amfenac, is performed by intraocular 
hydrolases;22 these enzymes are present in ocular tissues 
such as the cornea and iris/ciliary body, but are at their high-
est concentrations in the retina/choroid.27 This fact should 
provide an effective targeting of active drug to the macula, 
perhaps providing an advantage over conventional NSAIDs, 
none of which have a prodrug structure.
Preclinical studies do, in fact, support this hypothesis. 
Ex vivo studies using rabbit retina/choroid tissues 
demonstrated that nepafenac 0.1% reached its peak activity 
(suppression of prostaglandin production) sooner than 
diclofenac 0.1% (40 minutes vs 80 minutes).22 Moreover, 
nepafenac 0.1% produced greater and more sustained prosta-
glandin inhibition than diclofenac 0.1%.22 Ke and colleagues 
showed that compared to diclofenac, nepafenac exhibited 
6-fold faster corneal permeability, likely due to its neutral 
prodrug structure;27 logic would suggest that faster entry into 
the anterior chamber may translate to faster entry into the 
posterior chamber as well. Finally, results from an in vivo 
rabbit study of concanavalin A-induced retinal edema showed 
that nepafenac inhibited retinal inﬂ  ammation, as measured by 
blood–retinal barrier breakdown and prostaglandin synthesis, 
signiﬁ  cantly better than either diclofenac or ketorolac.28
Therefore, preclinical studies have demonstrated not only 
the targeted bioactivation of nepafenac, but also its increased 
absorption, greater activity and longer duration of action in 
the posterior segment relative to conventional NSAIDs; these 
characteristics suggest that nepafenac would perform favor-
ably compared to conventional NSAIDs in the prevention 
and treatment of retinal edema. The relatively small number 
of cases presented here support, although they cannot prove, 
this hypothesis. However, they do warrant formal investiga-
tion of nepafenac in placebo- and active-controlled trials for 
the treatment of CME.
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of nepafenac on acute and chronic CME, even in patients who 
have failed combination treatment with a steroid and a con-
ventional NSAID.23 Another report focuses on the successful 
use of nepafenac for the treatment of chronic uveitic CME.24 
Other reports demonstrate the resolution of macular edema 
by nepafenae 0.1% in steroid responders,25 and in patients 
with diabetic macular edema.26 In addition to CME treatment, 
nepafenac 0.1% may also have prophylactic activity against 
CME, as suggested by Wolf and colleagues, who recently 
published a retrospective study of 450 consecutive patients 
with CME showing that those treated with prednisolone 
alone had a higher incidence of CME than those treated with 
prednisolone + nepafenac 0.1%.4
The positive outcomes of the patients presented in the 
current study, showing reduction in/resolution of macular 
edema and improvement in visual acuity, provide additional 
evidence that nepafenac can effectively treat multiple types 
of CME. Therefore, this report adds to the body of evidence 
supporting an important role for nepafenac 0.1% in the 
treatment of macular edema. Of note, over half the cases 
responded to nepafenac treatment following failure of the 
conventional NSAID ketorolac. Although macular edema 
improved quickly in all three cases of acute CME in the 
current study, it must be noted that acute CME typically 
resolves spontaneously, making it difﬁ  cult to determine the 
role of nepafenac on this improvement.
A. Prior to treatment B. After 1 month of nepafenac  
prednisolone treatment
OD OD
Signal Strength (Max 10) Signal Strength (Max 10) 7 7
239
262
260
Microns
430
367
304
360 448 244
245
257
237
303
274
293
302 211 228
Microns
Figure 2 Acute pseudophakic CME: Patient #6 OCT images. A) The patient shows 
retinal edema, with a retinal thickness of 448 μm prior to treatment. B) The patient 
shows resolution of retinal edema, with a retinal thickness of 211 μm after one 
month of treatment with nepafenac + prednisolone.
Abbreviations: CME, cystoid macular edema; OCT, optical coherence tomography.Clinical Ophthalmology 2009:3 152
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Treatment of CME with nepafenac 0.1%
A. Prior to nepafenac treatment (690 microns) B. After 1 month of nepafenac treatment (262 microns)
Figure 3 Chronic/recalcitrant pseudophakic CME: Patient #12 OCT images. A) The patient shows retinal edema, with a retinal thickness of 690 μm prior to nepafenac 
treatment. B) The patient shows resolution of retinal edema, with a retinal thickness of 262 μm after one month of treatment with nepafenac.
Abbreviations: CME, cystoid macular edema; OCT, optical coherence tomography.
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